Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study
| Glavni autori: | , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Izdano: |
2006
|
| _version_ | 1826299570849579008 |
|---|---|
| author | Black, S Wilcock, G Haworth, J Hendrix, S Zavitz, K Christensen, D Binger, M Bass, S Laughlin, M Swabb, E |
| author_facet | Black, S Wilcock, G Haworth, J Hendrix, S Zavitz, K Christensen, D Binger, M Bass, S Laughlin, M Swabb, E |
| author_sort | Black, S |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T05:03:56Z |
| format | Conference item |
| id | oxford-uuid:d94555be-f10b-490f-a97f-61f70774dbd5 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T05:03:56Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:d94555be-f10b-490f-a97f-61f70774dbd52022-03-27T08:54:43ZEfficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on studyConference itemhttp://purl.org/coar/resource_type/c_5794uuid:d94555be-f10b-490f-a97f-61f70774dbd5Symplectic Elements at Oxford2006Black, SWilcock, GHaworth, JHendrix, SZavitz, KChristensen, DBinger, MBass, SLaughlin, MSwabb, E |
| spellingShingle | Black, S Wilcock, G Haworth, J Hendrix, S Zavitz, K Christensen, D Binger, M Bass, S Laughlin, M Swabb, E Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study |
| title | Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study |
| title_full | Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study |
| title_fullStr | Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study |
| title_full_unstemmed | Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study |
| title_short | Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study |
| title_sort | efficacy and safety of mpc 7869 r flurbiprofen a selective ab42 lowering agent in mild alzheimer s disease ad results of a 12 month phase 2 trial and 1 year follow on study |
| work_keys_str_mv | AT blacks efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT wilcockg efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT haworthj efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT hendrixs efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT zavitzk efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT christensend efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT bingerm efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT basss efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT laughlinm efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy AT swabbe efficacyandsafetyofmpc7869rflurbiprofenaselectiveab42loweringagentinmildalzheimersdiseaseadresultsofa12monthphase2trialand1yearfollowonstudy |